What are the signs, symptoms, and laboratory abnormalities of tumor lysis syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Symptoms of Tumor Lysis Syndrome

Tumor lysis syndrome presents with a constellation of clinical manifestations including nausea, vomiting, diarrhea, anorexia, lethargy, edema, fluid overload, hematuria, congestive heart failure, cardiac dysrhythmias, seizures, muscle cramps, tetany, syncope, and possible sudden death, typically occurring within 12 to 72 hours after initiation of cytoreductive therapy. 1

Laboratory Abnormalities

The metabolic derangements that define tumor lysis syndrome include:

  • Hyperuricemia (>8 mg/dL in adults) results from massive nucleic acid breakdown and can cause uric acid crystallization in renal collecting ducts, leading to acute oliguric renal failure 1, 2
  • Hyperkalemia (≥6 mmol/L) develops from rapid release of intracellular potassium and is life-threatening, producing cardiac irregularities such as arrhythmias, ventricular tachycardia, fibrillation, or cardiac arrest 1, 2
  • Hyperphosphatemia (>1.62 mmol/L) occurs from tumor cell lysis and can precipitate with calcium, worsening renal injury 1, 2
  • Hypocalcemia results from calcium-phosphate precipitation in tissues and may cause tetany and seizures when symptomatic 1, 2

Laboratory TLS is defined by two or more abnormal serum values (uric acid, potassium, phosphate, or calcium) occurring within 3 days before or 7 days after chemotherapy initiation 1

Clinical Symptoms by System

Cardiac Manifestations

  • Palpitations, arrhythmias, ventricular tachycardia, and cardiac arrest from hyperkalemia 1, 3
  • Congestive heart failure from fluid overload 1
  • Sudden death, with two of four deaths in one Burkitt's lymphoma cohort directly attributable to hyperkalemia 1, 3

Neuromuscular Effects

  • Muscle cramps and paresthesias from elevated potassium levels 1
  • Tetany and seizures from symptomatic hypocalcemia 1
  • Lethargy and syncope 1

Gastrointestinal Symptoms

  • Nausea, vomiting, diarrhea, and anorexia are common presenting symptoms 1

Renal Manifestations

  • Hematuria, oliguria, and acute renal failure from uric acid crystal deposition 1
  • Uremia (abnormally increased blood urea nitrogen) from multiple mechanisms including uric acid crystal deposition, calcium phosphate precipitation, and xanthine crystallization 1
  • Edema and fluid overload 1

Timing of Symptom Onset

Symptoms most commonly appear within 12 to 72 hours after initiation of cytoreductive therapy, though they may occur before chemotherapy starts in cases of spontaneous tumor lysis syndrome. 1, 4

Critical Pitfalls

The mortality rate for clinical TLS reaches 83% when significant complications develop, compared to 24% without clinical TLS 3. In solid tumors, mortality approaches 35% due to delayed recognition 2. Hyperkalemia is particularly dangerous, as it can progress rapidly from mild symptoms (muscle cramps, palpitations) to life-threatening arrhythmias and sudden cardiac death 1, 3. Continuous ECG monitoring is mandatory for all patients with hyperkalemia 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tumor Lysis Syndrome Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hyperkalemia Management in Tumor Lysis Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Spontaneous Tumor Lysis Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.